Comprehensive Analysis of a tRNA-Derived Small RNA in Colorectal Cancer

Yong Zhu1,2†, Shaoqiu Chen3,4†, Zhougui Ling3,5†, Andrew Winnicki3, Lilly Xu3, Shaun Xu3, Ting Gong3, Bin Jiang1*, Gang Huang6* and Youping Deng3*

1 National Medical Centre of Colorectal Disease, The Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China, 2 Department of Cell & Molecular Medicine, Rush University Medical Center, Chicago, IL, United States, 3 Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, United States, 4 Molecular Biosciences and Bioengineering Program, College of Tropical Agriculture and Human Resources, University of Hawaii at Manoa, Honolulu, HI, United States, 5 Department of Pulmonary and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China, 6 Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China

Colorectal cancer often presents as a highly variable disease with myriad forms that are at times difficult to detect in early screenings with sufficient accuracy, for which novel diagnostic methods are an attractive and valuable area of improvement. To improve colorectal cancer diagnosis and prognosis, new biomarkers that can be assembled into a diagnostic panel must be identified, and tRNA-derived small RNAs (tsRNAs) are a particularly interesting and increasingly visible new class of molecules to examine. In this study, small RNA-seq data were profiled for the expression of 104 human tsRNAs in tumor tissue and adjacent normal tissue samples, and a diagnostic model was built based on four differentially expressed tsRNAs: tRF-22-WB86Q3P92, tRF-22-WE8SPOX52, tRF-22-WE8S68L52, tRF-18-8R1546D2. Furthermore, the diagnostic model was validated by two independent validation datasets (AUC was 0.97 and 0.99), and a LASSO model was applied to develop a seven-tsRNA-based risk score model for colorectal cancer prognosis. Finally, a tsRNA-mRNA interaction network was established according to potential mRNA targets predicted by bioinformatic methods. In conclusion, the results suggest that abnormal expression of tsRNA in colorectal cancer may have a functional effect on tumor action and moreover, that some of the tsRNAs identified in this study with diagnostic and prognostic potential could be of clinical significance.

Keywords: colorectal cancer, tRNA-derived small RNAs, diagnosis, prognosis, random forest

INTRODUCTION

Colorectal cancer (CRC) is currently one of the most common types of cancers in the world, with incidence and mortality rates increasing over the last 25 years in adults under the age of 50 (1–3). In both sexes combined, CRC accounts for the third highest rate of cancer incidence at 10.2% cases and the second highest mortality rate at 9.2% (3–5). According to the WHO, in 2018, more than 1.8 million new cases of CRC were diagnosed worldwide, with 862,000 deaths, and the global burden is expected to balloon to 2.2 million new cases and 1.1 million deaths by 2030 (4). Moreover, given the growth and aging of the population, the global burden of CRC can only be expected to increase further, including in developing countries where the increasing rate of incidence is agragated largely by late presentation and inaccessibility to early screening.
CRC is not isolated to developing countries, but on the contrary is an issue much more pronounced in high HDI countries: for example, according to the CDC, in the United States alone, 141,270 new CRC cases emerged in 2016 with 52,286 deaths (5). However, despite these harrowing statistics, colorectal cancer is also one of the most preventable types of cancer with a high survival rate after early detection. The efficacy of early detection and prompt treatment of the disease is demonstrated markedly in developed countries, where early screening rates have escalated over the last decade and mortality has been on a largely downward trend overall (6–8). For example, patients who participated in flexible sigmoidoscopy for screening of CRC have shown significantly reduced incidence and mortality rates that were sustained over the long term, but the US Preventive Services Task Force still reports a lack of definitive evidence for a single-best screening approach, and current methods for early detection such as the endoscopy are typically fairly invasive (9, 10). The development of noninvasive, accurate, and accessible data-driven methods might contribute significantly to the establishment of socially normalized, regular CRC screenings for millions of adults around the world. Furthermore, significantly reducing barriers to access early screening methods would go a long way to preventing developing countries from inheriting the issues that accompany shifting diets and lifestyles, as well as perhaps even attenuate the asymmetric development of CRC along socioeconomic lines (1–3). This issue is, therefore, of great urgency, and the confluence of problems that CRC presents our society is highly multidimensional. Indeed, in recent years, the CDC has engaged in enormous movements to encourage increased CRC screening rates to at least 80% in every community by reducing screening barriers (5). Thus, the need for new methods of detecting CRC early presents itself both as a burgeoning need in developed countries as well as a new area of demand in developing countries with the potential for tremendous positive impact.

This study explores the potential of tRNA-derived small RNA (tsRNA) to address this immense need. In recent years, the study of small non-coding RNAs (ncRNAs) has expanded rapidly to become one of the hottest areas of research in the field with the revelation of their biological and even clinical significance. Many ncRNAs have been shown to play key roles in regulating cancer and are associated with a variety of biological processes, and moreover some are stable in the bloodstream where they could be used as the basis for a cancer screening with only a few drops of blood (11–14). Thus, ncRNAs are an alluring target for active translation into the clinic. In particular, tsRNAs are a novel type of regulatory small non-coding RNA that has attracted the attention across multiple subfields of biology both as an area that appears fertile for development of new early detection methods, and also for the allusion in recent studies to its participation in a variety of biological processes under diverse pathological and physiological conditions (15–18). Today, different forms of tsRNA are known to emerge from cleavage of tRNA or pre-tRNA at well-defined sites, and that they are not simply a degradation product but rather one that is precisely regulated (11). Moreover, recent research has shown that tsRNA disorders are associated with a number of different cancers as either oncogenic factors or tumor suppressors, and that their expression is related to cancer development and staging (19). In a recent study, tsRNAs were found to be upregulated in liver tumors, and even more importantly, the targeting of these tsRNAs with an oligonucleotide resulted in cell death both in vitro and in vivo (20). Additionally, in liver cancer, regulation of tsRNA expression was found to be associated with overall survival of the disease (21). Taken together, these important results indicate the potential clinical and biological importance of tsRNA, yet they also highlight the vast space for future research to improve our understanding of these ncRNAs. There are many questions about the biogenesis of tsRNA and their precise roles and mechanisms within the body that remain to be illuminated, and whether the expression profile of tsRNAs could present a stable bloodborne signal representative of the internal tumor state for use in a clinical setting. Research in tsRNAs promises exciting new applications and discoveries, and efforts to elucidate their poorly understood background and clinical significance represent an important and emerging facet of cancer research at large. tsRNAs are a prime candidate for further examination towards achieving the goal of addressing the immense needs for easily accessible, non-invasive, accurate early CRC screening methods described, and even as a potential therapeutic target.

METHODS

Dataset and Small RNA Sequence Processing

Discovery of tsRNAs and the independent validation set 1 were obtained from the Sequence Read Archives (SRA) public repository (SRP107326, SRP183064). The independent validation set 2 and prognostic dataset were downloaded from the TCGA data portal (https://tcga-data.ncl.nih.gov/tcga). All small RNA-seq were aligned using sRNAtools software to obtain tsRNA expression levels. The full details of this method have been published previously (22). Briefly, all miRNA-seq FASTQ files were con-verted to collapsed FASTA format after removal of adapters. The TCGA miRNA-seq BAM files are files that have removed adapters. Unprocessed FASTQ format reads had adapters trimmed and filtered for 16 nucleotides utilizing Cutadapt 2.1. Missing values was imputed by MetImp 1.2 (23).

Statistical Analysis

Adjacent normal tissue and tumor tissue were analyzed using the paired student t-test in building the diagnostic model, and statistically significant tsRNA sequences were selected. The diagnostic model was constructed using a random forest classifier on these selected tsRNA markers to differentiate colorectal cancer patients from controls. The Kaplan-Meier (KM) test was used for the analysis of the prognostic survival curve and the log-rank test to quantify the survival curve. The Cox regression model was applied in multivariable survival analysis. All analyses were implemented in R software (version 4.0.1). P-values less than 0.05 were statistically significant.

Target Prediction and GO Analysis

The RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/) algorithm was used to predict the potential binding targets of miRNAs indicated by significant prognostic tsRNAs (screening rules:
energy < -25 kcal/mol). GO analysis (www.geneontology.org/) was used to identify the predicted target genes, and all involved GO genes were assessed. Fisher’s test was used to calculate the significance level (p-value) of every GO gene, and the outcomes were adjusted using the FDR method in multiple hypothesis testing to classify statistically significant GO genes from differential significant gene enrichment. The network diagram was visualized with Cytoscape software (version 3.5.1).

Pathway Analysis
The statistically significant tsRNAs’ target gene enrichment analysis was performed by the KEGG pathway (www.kegg.jp/). The hypergeometric distribution of Fisher’s test informed calculation of all pathway weights (p-value) and was adjusted by the FDR. ShinyGo (http://bioinformatics.sdstate.edu/go/) was used to analyze biological process, cellular components, and identify molecular function in conjunction with Pfam and InterPro databases.

RESULTS
Altered Expression Profiles of tsRNAs
Supplementary Figure 1 displays the data processing workflow. Table 1 shows the clinicopathological characteristics of the three cohorts that were analyzed through small RNA-seq. In the discovery dataset, 104 paired colorectal cancer samples with adjacent normal tissue samples were analyzed by small RNA-seq and differentially expressed tsRNAs were extracted for both tumor and normal tissue (Figure 1A). Significantly expressed

| Cohort       | SRP107326 | TCGA   | SRP183064 |
|--------------|-----------|--------|-----------|
| Num. of patients |           |        |           |
| Adjacent Normal | 104       | 11     | 6         |
| Primary Tumor   | 104       | 603    | 6         |
| Age in years, median (IQR) | (55.7-68.2) | (57.0-65.8) |            |
| Sex            |           |        |           |
| Male, count (%) | 59(56.7)  | 315(52.2) |           |
| Race           |           |        |           |
| Asian          | 104       | 13     | 6         |
| White          | 308       |        |           |
| Black or African American | 71       |        |           |
| American Indian or Alaska | 1        |        |           |
| Native         | Not Reported | 210 |           |
| Treatment Type |           |        |           |
| Radiation Therapy | Not Reported | 307  | Not Reported |
| Pharmaceutical Therapy | Reported 296 |        |           |
| Stage          |           |        |           |
| Stage I        | 18        | 104    |           |
| Stage II       | 29        | 180    |           |
| Stage III      | 42        | 172    |           |
| Stage IV       | 13        | 89     |           |
| Not Reported   | 24        | 6      |           |
| Primary Diagnosis |           |        |           |
| Adenocarcinoma | 501       |        |           |
| other          | 68        |        |           |
| Events         |           |        |           |
| Death          | Not Reported | 478  | Not Reported |
| Alive          | Reported 125 |        |           |
| Follow Up time (days, IQR) | 638.0  | (370.5-1091.0) |            |
tsRNAs were selected (p<0.05, \(|\log_2 \text{Fold change}| > 1\)) to build the diagnostic model (Supplementary Table 1). The nomenclature contrasts the Mintbase naming method to avoid confusing labels in distinct databases.

**Multi-tsRNAs Diagnostic Model**

All 52 tsRNAs with dysregulated expression were selected for features in the random forest (RF) model. According to the RF mean decrease of accuracy and mean decrease in Gini entropy, four significant tsRNAs were picked: tRF-22-WB86Q3P92, tRF-22-WE8SPOX52, tRF-22-WE8S68L52, tRF-18-8R1546D2 (Figure 1B). Model performance was evaluated by testing out-of-bag (OOB) samples. We assessed the model performance by receiver operating characteristic curve (ROC curve). The four-tsRNA-based model has AUROC 0.93 (Figure 1C) in the discovery dataset. Two independent datasets were then applied to test the classification model. Based on the OOB predicted probabilities (Prob.), a diagnostic RF-score was calculated for the two independent validation datasets. The area under the receiver operating characteristic curve (AUC) was 0.97 and 0.99 (Figure 1C). Figures 1D–F shows the expression levels of the 4 tsRNAs in the three data sets.

**Multi-tsRNA Based Prognostic Model**

The expression data of 603 colorectal cancer patients informed the prognostic model from the TCGA dataset. A univariate Cox regression analysis was first performed of the overall survival based on each tsRNA. We further utilized a LASSO Cox regression model (Figure 2A) to build a prognostic model, including six of the seven significant tsRNAs: tRF-18-HSRVK7D2, tRF-33-PSQP4PW3FJI0W, tRF-33-PSQP4P

---

**FIGURE 2** | tsRNA prognostic panel. (A) Prognostic marker selection: Univariate-Cox and LASSO-Cox were applied to a cohort with survival data to identify seven markers' final determination. L1 norm is LASSO coefficient profiles of the 8 tsRNAs. A vertical line is drawn at the optimal value by 1 s.e. criteria and results in six non-zero coefficients. Five tsRNAs were selected in the LASSO Cox regression model. (B) Kaplan-Meier survival curve showing overall survival (OS) in patients without clinical characteristic in high risk and low risk score; (C) Kaplan-Meier survival curve showing overall survival (OS) in patients with clinical characteristic in high risk and low risk score; (D) Multivariate Cox regression analysis of the tsRNA-based prognostic model with OS. Event; *p < 0.05; **p < 0.001.
W3FJIKW, tRF-18-H9Q867D2, tRF-32-O7M8LOMLQHWU3, and tRF-16-I3FJQSD. We estimated the risk score for each patient according to individualized values of six tsRNAs: risk score = (0.094 x tRF-18-HSRVK7D2) + (0.268 x tRF-33-PSQP4PW3FJI0W) + (0.07 x tRF-33-PSQP4PW3FJIKW) - (0.08 x tRF-18-H9Q867D2) + (0.08 x tRF-32-O7M8LOMLQHWU3) - (0.01 x tRF-16-I3FJQSD). Figure 2B shows the disease-free survival curves of high-risk patients and low-risk patients (cutoff=-0.1). Low-risk patients have a better possibility of survival than high-risk patients (p<0.01).

**Multivariable Analysis**

To further establish the prognostic significance of tsRNAs in colorectal cancer, we also deployed the prognostic model in combination with other clinicopathological characteristics of colorectal cancer patients from the TCGA database (Figure 2C, p<0.001). Importantly, the previously identified association was maintained even after multivariate adjustment for clinico-pathological characteristics [p<0.05, HR 1.65(1.12-2.4)] (Figure 2D). These outcomes indicated the utility of a combination of our predictive tsRNAs and clinical factors.

**FIGURE 3** | Survival analysis at different cancer stages. Prognostic model in (A) Stage I; (B) Stage II; (C) Stage III and (D) Stage IV.
towards improving predictive prognosis accuracy. Moreover, survival curves were drafted according to the Kaplan-Meier method for the patients with risk score in different cancer stages (Figures 3A–D) and tumor stages (Supplementary Figure 2). However, prediction of the risk score in stage II was poor.

Bioinformatic Prediction
The significantly differentially expressed tsRNAs in the diagnostic and prognostic model were investigated using bioinformatic methods. First, the current understanding is that tsRNAs can achieve a miRNA-like form of action, interacting with mRNA targets to regulate gene expression. The interactions between tsRNAs and mRNA transcripts were predicted by the prediction tool RNAhybrid, including the binding sites’ location on the target, the critical region, and free energy of the imperative stability with graphic illustration. As a result, a tsRNA-mRNA interaction network was built using the mRNA associated with each tsRNA, identified according to the prediction score (Figure 4).

Second, a bioinformatic analysis was performed on all predicted target gene functions using GO analysis, KEGG pathway, and STRING-db enrichment. GO analysis comprises three domains of exploration: biological processes, cellular components, and molecular functions. STRING-db enrichment covers Pfam and interPro enrichment. Figure 5 shows that the most significant enrichment and the most meaningful terms identified were the intrinsic component of plasma membrane, adenylnucleotide binding, and positive regulation of cell communication in cellular components, molecular function, and biological processes (Figure 5).

In functional analysis of the tsRNAs, there is mounting evidence that tRFs have been related to acting as functional regulatory factors in immunity, physiological processes, and cellular metabolism (31, 32). Furthermore, some tsRNAs are dysregulated in various cancers, and that their expression is variable during cancer developing and staging (21, 33, 34).

DISCUSSION
The Human Genome and ENCODE Projects have shown that non-coding RNAs occupy more than 90% of the entire genome (24). Unlike DNA, non-coding RNA is more movable, flexible, and self-folds into a distinct structure that interacts with DNA, RNA, or protein (25, 26). Over the last several years, miRNA, lncRNA, snoRNA, and snRNA have been studied widely (27, 28). However, tsRNA, a new type of ncRNA, has not been studied extensively, especially with respect to cancer occurrence, progression, and metastasis.

This study developed and validated a novel diagnostic and prognostic tool based on tsRNAs to improve colorectal cancer diagnosis and disease recurrence prediction. Our results revealed that the diagnostic model could successfully classify patients into cancer and normal populations. The predictive model could also categorize patients into high-risk and low-risk groups with significant differences in 5-year disease-free survival. Despite the significant performance of tsRNAs in a CRC diagnostic model, the prognosis for patients with CRC at large remains poor. Moreover, the predictive model is inferior in CRC patients with stage II. Approximately one-quarter of CRC patients are diagnosed with stage II. While beneficial for stage III patients, the role of standard treatment is unestablished in stage II disease. At present, it is not possible to precisely differentiate between high-risk and low-risk prognoses for stage II patients (29, 30). Thus, there is an urgent need to explore additional prognostic markers to inform treatment plans for stage II CRC patients.

In functional analysis of the tsRNAs, there is mounting evidence that tRFs have been related to acting as functional regulatory factors in immunity, physiological processes, and cellular metabolism (31, 32). Furthermore, some tsRNAs are dysregulated in various cancers, and that their expression is variable during cancer developing and staging (21, 33, 34).
FIGURE 5 | Function enrichment analysis. (A) Biological process; (B) cellular component; (C) molecular function; STRING-db enrichment in (D) Pfam; (E) KEGG; (F) InterPro enrichment.
Notably, unusual tsRNAs are identified to bind to mRNA targets like the canonical miRNAs (35, 36). According to such developments, potential target-binding mRNAs for dysregulated tsRNAs were predicted and refined to build tsRNA-mRNA interactions for functional analysis. Predicted genes in STRING-db enrichment, cancer, Protein kinase domain, and P-loop containing nucleoside triphosphate hydrolase were the top signaling pathways affected by the dysregulated tsRNA-mRNA interaction. These enriched pathways may be the targets of the significant tsRNAs, presenting intriguing and potentially valuable avenues for future study.

Although models were established for the diagnosis and prognosis of CRC and the functions of these tsRNAs were predicted, questions that require further investigation still remain. Also, the diagnostic model built by cancer and adjacent normal is not as valuable as the prognostic model. Further prospective, large-scale, multicenter case-control studies are warranted to validate our results and identify the risk factors of CRC. In the predictive model, patients with CRC stage II need to be studied separately, and a new predictive model should be established. Moreover, further in vitro experimental verification is required to establish the predicted target mRNAs.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

**REFERENCES**

1. Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi REM, Corcione F. Worldwide Burden of Colorectal Cancer: A Review. Updates Surg (2016) 68(1):7–11. doi: 10.1007/s13304-016-0359-y
2. Ahmed MJ. Colon Cancer: A Clinician’s Perspective in 2019. Gastroenterol Res (2020) 13(1):1. doi: 10.14740/gr1239
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492
4. Organization WH. WHO Report on Cancer: Setting Priorities, Investing Wisely and Providing Care for All. World Health Organization (2020).
5. Courtney R. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General, 2014 US Department of Health and Human Services. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health (2014). p. 1081 Online (grey literature). Available at: http://www.surgeongeneral.gov/library/reports/50-years-of-progress. Wiley Online Library; 2015.
6. Rawla P, Sunkara T, Barsouk A. Epidemiology of Colorectal Cancer: Incidence, Mortality, Survival, and Risk Factors. Prog Gastroenterol (2019) 14(2):89. doi:10.5114/pg.2018.81072
7. da Silva RCF. Guide to Cancer Early Diagnosis. Rev Bras Cancerol (2017) 63(1):41–2. doi:10.36265/2176-9745.RBC2017v63n1.188
8. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin (2015) 65(2):87–108. doi:10.3322/caac.21262
9. Miller EA, Pinsky PF, Schoen RE, Prorok PC, Church TR. Effect of Flexible Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality: Long-Term Follow-Up of the Randomised US PLCO Cancer Screening Trial. Lancet Gastroenerol Hepatol (2019) 4(2):101–8. doi:10.1016/S2468-1253(18)30358-3
10. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for Colorectal Cancer in Adults at Average Risk: A Summary of the Evidence for the US Preventive Services Task Force. Ann Intern Med (2002) 137(2):132–41. doi:10.7326/0003-4819-137-2-200207160-00015
11. Slack FJ, Chinnaian AM. The Role of Non-Coding RNAs in Oncology. Cell (2019) 179(5):333–55. doi:10.1016/j.cell.2019.10.017
12. Sirivardhana C, Khadka VS, Chen JJ, Deng Y. Development of a miRNA-seq Based Prognostic Signature in Lung Adenocarcinoma. BMC Cancer (2019) 19(1):1–10. doi:10.1186/s12885-018-5206-8
13. Chen H, Liu H, Zou H, Chen R, Dou Y, Sheng S, et al. Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human Cancers. J Cancer (2016) 7(5):490. doi:10.7373/jca.12351
14. Fang R, Zhu Y, Hu L, Khadka VS, Ai J, Zou H, et al. Plasma microRNA Pair Panels as Novel Biomarkers for Detection of Early Stage Breast Cancer. Front Physiol (2019) 9:1879. doi:10.3389/fphys.2018.01879
15. Hauusecker D, Huang Y, Lau A, Parameswaran P, Fire AZ, Kay MA. Human tRNA-Derived Small RNAs in the Global Regulation of RNA Silencing. RNA (2010) 16(4):673–95. doi:10.1261/rna.200810
16. Lee YS, Shibata Y, Malhotra A, Dutta A. A Novel Class of Small RNAs: tRNA-Derived RNA Fragments (tRFs). Genes Dev (2009) 23(22):2639–49. doi:10.1101/gad.1837609
17. Yamasaki S, Ivanov P, Hu G-F, Anderson PJ. Angiogenin Cleaves tRNA and Promotes Stress-Induced Translational Repression. J Cell Biol (2009) 185(1):35–42. doi:10.1083/jcb.200811106
18. Deng Y, Zhu Y, Wang H, Khadka VS, Hu L, Ai J, et al. Ratio-Based Method to Identify True Biomarkers by Normalizing Circulating ncRNA Sequencing and Quantitative PCR Data. Anal Chem (2019) 91(10):6746–53. doi: 10.1021/acs.analchem.9b00821

19. Maute RL, Schneider C, Sumazin P, Holmes A, Califano A, Basso K, et al. tRNA-Derived microRNA Modulates Proliferation and the DNA Damage Response and Is Down-Regulated in B Cell Lymphoma. Proc Natl Acad Sci (2013) 110(4):1404–9. doi: 10.1073/pnas.1206761110

20. Kim HK, Fuchs G, Wang S, Wei W, Zhang Y, Park H, et al. A transfer-RNA-Derived Small RNA Regulates Ribosome Biogenesis. Nature (2017) 552 (7683):57–62. doi: 10.1038/nature25005

21. Balatti V, Nigita G, Veneziano D, Drusco A, Stein GS, Messier TL, et al. tsRNA Expression Panels as Novel Biomarkers for Early-Stage Lung Adenocarcinoma Screening. Lung Cancer.

22. Zuo Y, Chen S, Yan L, Hu L, Bowler L, Zitello E, et al. Development of a tRNA-Derived Small RNA Diagnostic and Prognostic Signature in Liver Cancer. Genes Dis (2021). doi: 10.1016/j.gendis.2021.01.006

23. Wei R, Wang J, Su M, Jia E, Chen T, et al. Missing Value Imputation Approach for Mass Spectrometry-Based Metabolomics Data. Sci Rep (2018) 8 (1):1–10. doi: 10.1038/s41598-017-19120-0

24. Guh C-Y, Hsieh Y-H, Chu H-P. Functions and Properties of Nuclear lncRNAs — From Systematically Mapping the Interactomes of IncRNAs. J Biomed Sci (2020) 27(1):1–14. doi: 10.1186/s12929-020-00640-3

25. Ransohoff JD, Wei Y, Khavari PA. The Functions and Unique Features of Long Intergenic Non-Coding RNA. Nat Rev Mol Cell Biol (2018) 19(3):143. doi: 10.1038/nrm.2017.104

26. Porto FW, Daulatabad SV, Janga SC. Long Non-Coding RNA Expression Levels Modulate Cell-Type-Specific Splicing Patterns by Altering Their Interaction Landscape With RNA-Binding Proteins. Genes (2019) 10(8):593. doi: 10.3390/genes10080593

27. Hu L, Ai J, Long H, Liu W, Wang X, Zuo Y, et al. Integrative microRNA and Gene Profiling Data Analysis Reveals Novel Biomarkers and Mechanisms for Lung Cancer. Oncotarget (2016) 7(8):8441. doi: 10.18632/oncotarget.7264

28. Dou Y, Zhu Y, Ai J, Chen H, Liu H, Borgia JA, et al. Plasma Small ncRNA Pair Panels as Novel Biomarkers for Early-Stage Lung Adenocarcinoma Screening. BMC Genom (2018) 19(1):1–10. doi: 10.1186/s12864-018-4862-z

29. Schepeler T, Reintert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dryskjot L, et al. Diagnostic and Prognostic microRNA Signatures in Stage II Colon Cancer. Cancer Res (2008) 68(15):6416–24. doi: 10.1158/0008-5472.CAN-07-6110

30. Dotan E, Cohen SJ. Challenges in the Management of Stage II Colon Cancer. Semin Oncol (2011) 38:511–20. doi: 10.1053/j.seminoncol.2011.05.005

31. Chou N-T, Kageyama R, Ansel KM. Selective Export Into Extracellular Vesicles and Function of tRNA Fragments During T Cell Activation. Cell Rep (2018) 25(12):3356–70.e3354. doi: 10.1016/j.celrep.2018.11.073

32. Qin C, Feng H, Zhang C, Zhang X, Liu Y, Yang DG, et al. Differential Expression Profiles and Functional Prediction of tRNA-Derived Small RNAs in Rats After Traumatic Spinal Cord Injury. Front Mol Neurosci (2020) 12:326. doi: 10.3389/fnmol.2019.00326

33. Balatti V, Pekarsky Y, Croce CM. Role of the tRNA-Derived Small RNAs in Cancer: New Potential Biomarkers and Target for Therapy. NPJ Breast Cancer (2017) 135:173–87. doi: 10.1038/bcr.2017.007

34. Wang J, Ma G, Ge H, Han X, Mao X, Wang X, et al. Circulating tRNA-Derived Small RNAs (tsRNAs) Signature for the Diagnosis and Prognosis of Breast Cancer. NPJ Breast Cancer (2021) 7(1):1–5. doi: 10.1038/s41523-020-00211-7

35. Luo S, He F, Luo J, Dou S, Wang Y, Guo A, et al. Drosophila tsRNAs Preferentially Suppress General Translation Machinery Via Antisense Pairing and Participate in Cellular Starvation Response. Nucleic Acids Res (2018) 46 (10):5250–68. doi: 10.1093/nar/gky189

36. Li P-F, Guo S-C, Liu T, Cui H, Feng D, Yang A, et al. Integrative Analysis of Transcriptomes Highlights Potential Functions of transfer-RNA-Derived Small RNAs in Experimental Intracerebral Hemorrhage. Aging (Albany NY) (2020) 12(22):22794. doi: 10.18632/aging.103938

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.